-
Overseas Marketing of Furmonertinib Following Avitinib and Almonertinib
PharmaSources/Dopine
August 06, 2021
According to Allist Pharmaceuticals' announcement on June 30, Allist intends to enter into an agreement with ArriVent Biopharma (hereinafter referred to as "ArriVent") to authorize ArriVent the right to exclusively develop.
-
Which one of new dosage forms of nasal spray vaccine for COVID-19 will be successful?
PharmaSources/Big Cat of Medical Field
August 06, 2021
According to the latest news on March 24, 2021 (last week), CanSino (688185.SH, 06185.HK) inhaled COVID-19 vaccine was approved by the National Medical Products Administration.
-
Having Applied for IPO to HKEX, What to Expect on Advaccine R&D Pipelines beyond COVID-19 DNA Vaccine
PharmaSources/Yefenghong
August 06, 2021
An army of enterprises sought for IPO at Hong Kong, S.A.R., China in the almost first half of 2021. Not long ago, a prospectus submitted by Beijing Advaccine Biotechnology (hereinafter, "Advaccine") for listing caused a sensation, and the launch of its co
-
Overview of COVID-19 Vaccination in Progress in China
PharmaSources/Xiaoyaowan
August 06, 2021
Up to now, 10 COVID-19 vaccines have been marketed worldwide, including two RNA vaccines from Pfizer & BNT and Modernam, four adenoviral vector vaccines from AstraZeneca, Johnson & Johnson, Gamaleya and CanSino, three inactivated viral vaccines from CNBG
-
New Progress of Potential "Specific Drugs" for COVID-19: Masitinib + S2H97
PharmaSources/Chuxin
August 02, 2021
Since the outbreak of COVID-19 at the end of 2019, it has spread all over the world. Up to now, more than 190 million confirmed cases of COVID-19 have been reported worldwide, and more than 4.11 million patients have died, causing great disasters.
-
Cocktail COVID-19 Neutralizing Antibody was Officially Approved in Japan to Build a Second Line of Defense
PharmaSources/Xiaoyaowan
August 02, 2021
Recently, Ronapreve, a product of Roche Pharmaceuticals, was approved by the Japanese Ministry of Health, Labour and Welfare for the treatment of mild to moderate COVID-19 patients by intravenous infusion.
-
Rec-Biotechnology Went to Hong Kong, S.A.R., China IPO, Aiming at the HPV Vaccine Market Worth Tens of Billions and Creating an Innovation Engine of Comprehensive Vaccine
PharmaSources/Yefenghong
August 02, 2021
On July 16, Rec-Biotechnology submitted its prospectus to HKEX and was accepted. Rec-Biotechnology is an innovative vaccine company, and its core product, Human Papillomavirus 9-valent Vaccine, Recombinant, is in Phase III clinical trial stage.
-
Chinese BTK Inhibitor Orelabrutinib Gone Global, What Other Drugs Have Been Ok'd Overseas in 2021
PharmaSources/Dopine
July 26, 2021
On July 13, InnoCare Pharma and Biogen made joint announcement that they have entered into an agreement on the license and cooperation of the BTK inhibitor Orelabrutinib.
-
Covid-19 Oral Medicine -- a Link to be focused on Against Epidemic
PharmaSources/Chuxin
July 26, 2021
In the wake of the outbreak of the COVID-19, the globally cumulative infected population has capped 100 million, which poses a huge impact on human activities.
-
Sun Pharma's SMO inhibitor Sonidegib at $175m about to be granted in China
PharmaSources/Dopine
July 26, 2021
On July 13th, the status of Class 5.1 import application for "Sonidegib Phosphate Capsules" by Sun Pharmaceuticals/Jemincare progressed to "under review" at the NMPA, and it is foreseen that it will be duly approved soon.